| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | 2,9 M € | +10.9% | 2,6 M € | -3.1% | 2,7 M € | +1.1% | 2,6 M € | +15.1% | 2,3 M € | +2.8% | 2,2 M € | +8.1% | 2,1 M € | -10.3% | 2,3 M € | +7.1% | 2,2 M € | |||||||||
| Gross margin | 20,8 k € | -59.0% | 50,7 k € | +150.4% | -100,7 k € | -57.9% | -63,8 k € | -174.9% | 85,2 k € | +36.8% | 62,3 k € | -6.3% | 66,4 k € | -52.2% | 138,9 k € | — | — | — | — | — | — | — | — | — | ||||||||||
| EBITDA | 20,0 k € | -56.5% | 46,1 k € | +142.8% | -107,6 k € | -48.9% | -72,3 k € | -199.5% | 72,6 k € | +105.2% | 35,4 k € | -41.7% | 60,7 k € | -53.7% | 131,1 k € | -35.7% | 203,8 k € | +445.3% | 37,4 k € | +17.4% | 31,8 k € | -84.8% | 208,8 k € | -34.3% | 317,9 k € | +48.4% | 214,1 k € | +8.6% | 197,1 k € | -57.6% | 465,1 k € | -4.0% | 484,5 k € | |
| Operating profit | 20,0 k € | -56.5% | 46,1 k € | +142.8% | -107,6 k € | -48.9% | -72,3 k € | -199.5% | 72,6 k € | +105.2% | 35,4 k € | -41.7% | 60,7 k € | -53.7% | 131,1 k € | -35.7% | 203,8 k € | +445.3% | 37,4 k € | +17.6% | 31,8 k € | -84.7% | 208,2 k € | -34.4% | 317,2 k € | +48.6% | 213,4 k € | +8.9% | 196,1 k € | -57.8% | 464,6 k € | -4.1% | 484,5 k € | |
| Profit/loss | 19,3 k € | -62.2% | 50,9 k € | +140.8% | -124,8 k € | -58.6% | -78,7 k € | -252.8% | 51,5 k € | +107.6% | 24,8 k € | -38.9% | 40,6 k € | -55.8% | 91,9 k € | -34.0% | 139,1 k € | +276.2% | 37,0 k € | -22.7% | 47,8 k € | -70.9% | 164,5 k € | -29.9% | 234,8 k € | +41.6% | 165,8 k € | +5.4% | 157,3 k € | -52.6% | 331,6 k € | -1.3% | 336,2 k € | |
| Equity | 197,4 k € | +10.8% | 178,1 k € | +40.0% | 127,2 k € | -49.5% | 252,1 k € | -23.8% | 330,8 k € | +18.5% | 279,3 k € | -21.2% | 354,4 k € | +12.9% | 313,8 k € | -39.9% | 522,0 k € | -72.3% | 1,9 M € | +2.0% | 1,8 M € | -24.6% | 2,4 M € | +7.2% | 2,3 M € | +11.5% | 2,0 M € | +8.8% | 1,9 M € | -10.4% | 2,1 M € | +18.7% | 1,8 M € | |
| Total assets | 352,4 k € | -38.4% | 572,4 k € | -5.6% | 606,2 k € | -6.0% | 644,7 k € | -28.9% | 906,4 k € | -25.6% | 1,2 M € | +97.8% | 615,8 k € | -13.4% | 710,7 k € | -15.4% | 840,1 k € | -62.2% | 2,2 M € | -3.0% | 2,3 M € | -12.4% | 2,6 M € | +2.3% | 2,6 M € | +7.7% | 2,4 M € | +12.0% | 2,1 M € | -13.3% | 2,4 M € | +12.7% | 2,2 M € | |
| Debts | 155,0 k € | -60.7% | 394,3 k € | -17.7% | 478,9 k € | +78.7% | 268,1 k € | -53.4% | 575,6 k € | -38.6% | 937,8 k € | +258.9% | 261,3 k € | -34.2% | 396,9 k € | +24.8% | 318,1 k € | -6.5% | 340,2 k € | -23.9% | 447,0 k € | +163.1% | 169,9 k € | -38.2% | 274,8 k € | -16.0% | 327,3 k € | +37.1% | 238,7 k € | -31.2% | 346,7 k € | -13.7% | 401,9 k € | |
Public limited company · Deinze · incorporated on 27/05/1987
Public limited company profitable and well capitalised.
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
OROPHARMA is a Public limited company incorporated in 1987. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Deinze.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette